Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Expenses (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Accumulated Expenses for 11 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 21.35% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 million, a 21.35% decrease, with the full-year FY2025 number at $9.5 million, down 21.35% from a year prior.
  • Accumulated Expenses was $9.5 million for Q4 2025 at Cartesian Therapeutics, up from $7.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $15.6 million in Q4 2023 to a low of $6.8 million in Q1 2021.
  • A 5-year average of $10.6 million and a median of $10.0 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 39.56% in 2022, then crashed 30.69% in 2024.
  • Cartesian Therapeutics' Accumulated Expenses stood at $10.5 million in 2021, then surged by 33.71% to $14.1 million in 2022, then rose by 10.57% to $15.6 million in 2023, then dropped by 22.45% to $12.1 million in 2024, then decreased by 21.35% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Accumulated Expenses are $9.5 million (Q4 2025), $7.7 million (Q3 2025), and $8.0 million (Q2 2025).